The use of GnRH agonists in precocious puberty

D Mul and I A Hughes

Department of Pediatrics, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands and 1Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK

(Correspondence should be addressed to EGAH van Mil at Department of Paediatrics, Jheronimus Bosch Medical Centre, PO Box 90153, 5200 ME, s’Hertogenbosch, The Netherlands; Email: vanmil@jbz.nl)

Abstract

In this review several aspects of gonadotrophin releasing hormone agonists (GnRHa) treatment in central precocious puberty (CPP) are highlighted. These include issues of the definition of precocity, assessment of CPP and thelarche variants. Indications for treatment with GnRH agonists are discussed, not only in CPP but also in children with other reasons to suppress central activation, e.g. adopted or developmental retardation. Finally, outcome data are summarized, both on growth and psychosocial parameters.

Introduction

GnRH agonist treatment in reproductive medicine is mainly devoted to two areas of interest. The first is the application in assisted reproduction, aimed at desensitization of the pituitary during ovarian stimulation (1). The second area of interest is the administration of long-acting GnRHa preparations in the treatment of early or precocious puberty, where prolonged suppression of pituitary gonadotrophin secretion is required.

Central precocious puberty (CPP) is characterized by premature awakening of the hypothalamic GnRH pulse generator with subsequent pulsatile gonadotrophin secretion. New insights into the physiology and pathophysiology of puberty have revealed the importance of both genetic and environmental factors in controlling the onset of puberty. For example, the potential role of exogenous pollutants (endocrine disrupting chemicals) in altering the age of onset of puberty is a phenomenon that highlights the sensitivity of the organism to environmental changes (2). There is also the argument from an evolutionary perspective that the trend towards an earlier onset of puberty as applied to females is an affirmation of the effects of adaptive mechanisms determined by distant ancestors (3). While early, as opposed to precocious, puberty may be considered an appropriate response biologically, there has evolved a mismatch because of delayed psychosocial maturation.

The identification of mutations in the gene for GPR54 (KISS1R), a G-protein-coupled receptor, has highlighted one cause of hypogonadotrophic hypogonadism with delayed puberty (4). Mutations affecting the ligand, KISS1, are also described in association with gonadotrophin-dependent precocious puberty (5). The present view is that kisspeptins have an essential role in the activation of the gonadotrophic axis (6). Despite these developments, the mainstay of the treatment of CPP is still targeted at the desensitization of the pituitary by agonists of native GnRH (7). This review summarizes the use of GnRHa in children, with particular emphasis on CPP and early puberty. Other applications in paediatric medicine will be discussed briefly.

Issues in defining precocity

It has been proposed that the age of onset of female puberty has declined based primarily on data gathered in the United States (8). However, the trend was more pronounced in black girls and similar data have not been replicated in Europe. Consequently, this review adheres to the current lower age limit of 8 years in girls (presenting with Tanner stage B2) and of 9 years in boys (Tanner G2 and/or testicular volume \( \geq 4 \) ml). Children with pubertal development just above these age limits (e.g. a girl with B2 at 9.0 years of age) can be construed as just demonstrating early normal puberty. Nevertheless, in clinical practice, this raises similar concerns by parents as when true CPP occurs. For practical purposes, girls between 8 and 10 years, and boys between 9 and 11 years at onset of puberty have an early, but not precocious puberty, yet may in certain circumstances need to be considered for treatment intervention.

This paper was presented at the 5th Ferring International Paediatric Endocrinology Symposium, Baveno, Italy (2008). Ferring Pharmaceuticals has supported the publication of these proceedings.

© 2008 European Society of Endocrinology

DOI: 10.1530/EJE-08-0814

Online version via www.eje-online.org
A special group for consideration is children who have migrated from developing countries following international adoption and where menarche in girls is generally later than those in the Western countries (9). Studies from Denmark showed that adopted children were 10–20 times more likely to develop precocious puberty when compared with a reference Danish population (10). The aetiology of early maturation in adopted children, mainly girls, is not understood. The female preponderance implies a factor of central origin, but peripheral signals may be permissive or enhancing. Suggested contributing factors have included low birth weight, perinatal stress, changes in diet and exposure to environmental chemicals with endocrine disrupting effects in the country of origin (11).

CPP and overlaps with thelarche variants

Analysis of a large French sample of 353 girls with precocious puberty has highlighted the difficulty in sometimes distinguishing between premature thelarche and CPP in girls with breast development before the age of 8 years (12). Sixty per cent of the presentation occurred at 7–8 years of age; the principal anthropometric indices were an increased height SDS (≥ +2 SDS) in 54%, a growth rate ≥ +2 SDS in 46% and bone age advance ≥ 2 years in 33%. There is a heterogeneity in the pattern of presentation ranging from rapidly progressing puberty to a slowly progressive form, or even complete regression in pubertal signs and no need for treatment (13).

It has been suggested that thelarche variants represent different positions along a continuum of hypothalamic GnRH neuronal activation (14). The natural history of progression from premature thelarche (defined by bone age advancement within 2 s.d. of normal, normal growth rate and FSH-predominant responsiveness to acute GnRH stimulation) to CPP was investigated in 100 girls, with a mean age of 5.1 years (15). Their follow-up indicated a 14% progression rate. Some clarity has been achieved through the European Society for Paediatric Endocrinology classification of endocrine diagnoses (16). Early onset of premature thelarche occurring before 3 years of age generally regresses between 6 months and 6 years after onset. A later onset is usually a slowly progressive form of precocious puberty which may even regress. Both forms need regular follow-up but treatment is rarely indicated.

Precocious puberty: assessment

The following components need to be included in the evaluation of a child presenting with precocious puberty.

(i) Chronology of the appearance of secondary sexual characteristics before the age of 8 years in a girl (B2 stage) or before the age of 9 years in a boy (G2 and/or testicular volume ≥ 4 ml). The rate of progression of pubertal signs and any accompanying growth spurt (the ‘tempo’ of puberty) is recorded. Symptoms suggestive of an intracranial lesion such as headache and visual disturbance should be noted.

(ii) Physical examination is focused on quantifying puberty by Tanner staging and anthropometric measurements are plotted on appropriate growth charts. The full examination includes neurological evaluation and dermatological features of diagnostic pointers for conditions such as neurofibromatosis and McCune–Albright syndrome.

(iii) Bone age assessment provides an indication of skeletal advancement from excess sex steroids and can also be used to estimate final height.

(iv) Ultrasound of the ovaries and testes may reveal the presence of a tumour as a non-central or gonadotrophin-independent cause of the precocious puberty. Pelvic ultrasound in girls may differentiate between premature thelarche and precocious puberty, particularly in relation to uterine size.

(v) The key endocrine investigation is to determine the LH and FSH response to acute GnRH stimulation in order to distinguish between central and non-central (peripheral) forms of precocious puberty. Several test protocols are described; the one commonly used is measurement of LH and FSH at baseline and 20 and 60 min after 100 µg GnRH given intravenously. It is essential to employ sensitive gonadotrophin assays; indeed, this may permit differentiation by analysis of basal LH levels only (17).

(vi) Magnetic resonance imaging of the brain is indicated in all boys with CPP given the high prevalence of organic causes in this group. Most centres would probably also routinely perform this imaging in all girls with precocious puberty, although the prevalence of an organic lesion is much lower when early puberty presents after 6 years of age (18).

A classification of the causes of precocious puberty is traditionally based on a subdivision into gonadotrophin-dependent and gonadotrophin-independent categories, the acute GnRH stimulation test ‘underpinning this subdivision’. Table 1 lists causes of precocious puberty according to such a classification. The remainder of this review refers to gonadotrophin-dependent precocious puberty in view of the focus on GnRH analogues.

Indications for treatment with GnRHa

A number of applications of GnRHa treatment apply in paediatric and adolescent practice. Precocious puberty
poses the problems of inappropriate early biological maturation at variance with psychological immaturity. Significant impairment of final height in untreated CPP has dominated the rationale for intervening with GnRH treatment (19). It has been calculated that height loss has dominated the rationale for intervening with GnRH treatment (19). It has been calculated that height loss is of the order of 20 and 12 cm in boys and girls respectively (20). Few studies have evaluated psychosocial outcome following early or precocious puberty, but a long-term Swedish study reported more antisocial behaviour in adolescence and lower academic achievement in adulthood (21). There is evidence that normal, early maturing adolescents are more likely to have sexual intercourse and engage in substance abuse at an earlier age than normal or late maturing adolescents (22). GnRHa treatment may be indicated to halt menses for hygienic reasons in some girls with severe cerebral palsy or developmental retardation. Girls with cerebral palsy start puberty earlier than normal girls but menarche is delayed by about 1 year (23). A number of options are available to manage menstruation and contraception in adolescents with severe learning difficulties (24). Depo-Provera (Pfizer) is probably less cumbersome than GnRHa in the longer term: surgical intervention is seldom necessary. GnRHa is now used to suppress puberty in adolescents with gender dysphoria and contemplating cross-hormone treatment and later genital surgery (25). Current controversies centre on whether such treatment should be instigated at an early Tanner stage or when puberty is almost complete (26). The following section concentrates solely on the application of GnRHa treatment in the management of precocious puberty.

### GnRHa treatment

Several preparations of GnRHa are currently available. These include Leuprorelin, Triptorelin and Goserelin, which are each available as monthly and 3-monthly depot preparations. A 12-month implant (Histrelin) is also available but currently only in the United States (27). Short-acting preparations that need to be delivered one to three times daily by nasal spray are also available but are not as efficient as sustained release preparations in suppressing gonadotrophin secretion. The rationale of continuous GnRH secretion for the suppression of pubertal development is that the pituitary gonadotrophs are subject to prolonged rather than intermittent (pulsatile) exposure to the RH (7). Following an initial ‘flare’ in LH and FSH secretion, the pituitary gonadotroph receptors become desensitized and LH and FSH secretion is subsequently suppressed. To achieve prolonged agonist activity, the GnRH decapeptide is modified by replacing the sixth amino acid, glycine, with a hydrophobic D-amino acid. Treatment is usually started with a monthly depot preparation given in a dose of 3.75 mg by s.c. or i.m. injection. A withdrawal bleed may occur in some girls following the first GnRHa injection. Some centres co-administer cyproterone acetate for a few weeks to counter the effects of the initial ‘flare’ in gonadotrophin secretion before desensitization is established. The acute GnRH stimulation test is repeated after a few months to determine whether LH and FSH levels are suppressed. Later, it may be possible to maintain adequate gonadotrophin suppression using a 3-monthly long-acting preparation, using a dose of 11.25 mg. Triptorelin (Decapeptyl SR) is the only 3-monthly long-acting preparation, using a dose of 11.25 mg. Some preparations of GnRHa are currently available. Oestradiol and testosterone concentrations. Oestradiol and testosterone levels were suppressed to prepubertal levels by month 3 in 96 and 70% of girls and boys respectively. If suppression of hormone concentrations. Oestradiol and testosterone levels were suppressed to prepubertal levels by month 3 in 96 and 70% of girls and boys respectively. If suppression of hormone

### Table 1 Classification of precocious puberty.

<table>
<thead>
<tr>
<th>Gonadotrophin dependent</th>
<th>CNS lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothalamic hamartoma</td>
<td>Tumours: optic glioma, germ cell tumour, astrocytoma</td>
</tr>
<tr>
<td>Congenital malformations: arachnoid cyst, hydrocephalus, neural tube defect</td>
<td>Acquired: head trauma, cranial irradiation, infection, perinatal asphyxia</td>
</tr>
<tr>
<td>Non-CNS lesion</td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Activating KISS1 and GPR54</td>
<td>Endocrine disruptor exposure; excess endogenous steroids (e.g. CAH)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gonadotrophin independent</th>
<th>Gonadal lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leydig cell tumour, granulosa cell tumour</td>
<td>Activating LH receptor mutation (testotoxicosis)</td>
</tr>
<tr>
<td>GNAs gene activating somatic mutation (McCune–Albright syndrome)</td>
<td>Adrenal tumours</td>
</tr>
<tr>
<td>hCG secreting tumours</td>
<td>Congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>Long-standing, untreated primary hypothyroidism</td>
<td>Exogenous sex steroids</td>
</tr>
<tr>
<td>Pubertal variants</td>
<td>Premature thelarche</td>
</tr>
<tr>
<td>Premature adrenarche</td>
<td>Isolated premature menarche</td>
</tr>
</tbody>
</table>

### Table 2 GnRH-stimulated concentrations of LH and FSH before and after GnRHa treatment.

<table>
<thead>
<tr>
<th>LH peak</th>
<th>FSH peak</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤3 IU/l</td>
<td>Peak (IU/l)</td>
</tr>
<tr>
<td>n/N (%)</td>
<td>(IU/l)</td>
</tr>
</tbody>
</table>

| ITT population (n=64) | | | |
|-----------------------|---|---|
| Baseline | 0/64 (0) | 21.0±13.7 | 10.9±4.7 |
| Month 3 | 53/62 (85) | 3.1±6.3* | 2.6±3.4* |
| Month 6 | 60/62 (97) | 1.3±0.9* | 1.7±1.1* |
| Month 12 | 56/59 (95) | 1.7±2.9* | 2.0±1.7* |

| Per-protocol population (n=38) | | | |
|-----------------------------------------|---|---|
| Baseline | 0/38 (0) | 21.3±14.5 | 10.7±4.7 |
| Month 3 | 37/38 (97) | 1.2±0.7* | 1.4±0.8* |
| Month 6 | 37/38 (97) | 1.2±0.7* | 1.7±1.1* |
| Month 12 | 37/38 (97) | 1.7±3.2* | 2.2±1.9* |

Results are given as mean±s.d. *P<0.001 with respect to baseline. ITT refers to intend-to-treat population; the per-protocol population is a subset of the ITT population and had received all four quarterly injections. (Reproduced from Ref. (28), with permission).
levels is insufficient, the frequency of GnRHa injections can be increased; the alternative is to revert to the 1-monthly depot preparation, but at a higher dose.

Effect of GnRHa treatment on final height

Despite GnRH analogue treatment being used in precocious puberty for more than 20 years, there are no randomized controlled trials to evaluate the effect of GnRHa on a final height compared with untreated controls. The majority of studies compare pretreatment predicted final height data with final attained adult height. The effectiveness of GnRHa treatment can probably only be evaluated by comparing final height data in current treated cohorts with historical data from untreated patients. The analysis of final height outcome data is compounded by a number of factors that influence accuracy and relevance of the end result. Comparing historical with contemporary data may be affected by the influence of secular trends in human growth over the past 25 years. Many studies have had to rely on height prediction, rather than actual final height, to evaluate the effect of treatment intervention. The use of bone ages is insufficiently reliable, particularly when skeletal maturation is markedly advanced at presentation. Nevertheless, the use of Bayley and Pinneau tables for average children appears to be the preferred methodology for height prediction.

As in many endocrine disorders where final height is a measure of response to treatment, the age at which treatment is initiated, its duration and the magnitude of bone age advancement at the start of treatment are influential factors. Unlike disorders treated with GH, the dose of GnRHa is irrelevant, as long as adequate gonadotrophin suppression is achieved for the duration of the treatment. All these heterogeneous factors make the formulae used for predicted heights of disputable value. In a retrospective single-centre study of 87 girls with idiopathic CPP treated for 3–8 years, adult height was 159.8 ± 5.3 cm and represented a 9.5 ± 4.6 cm increment in height when compared with predicted height using Bayley and Pinneau tables for average children.

Overall, the majority of studies indicate some beneficial effect of GnRHa treatment on final height in girls when compared with initial height predictions. The increment can range from 3 to 10 cm, although realistically, a height gain of 4–6 cm after at least 3–4 years of GnRHa treatment is the estimate for a girl with CPP. A shorter interval between the age of onset of puberty and starting treatment was a determining factor for achieving normal adult height. The best independent predictor of growth during the period of GnRHa therapy in girls is bone age. This observation can be interpreted by assuming that the slowing of growth during treatment is a function of premature growth plate senescence induced by previous exposure to excess oestrogens.

Outcome data for final height are even less established for boys in whom the incidence of precocious puberty is lower than in girls. An analysis of final height from 11 studies showed a remarkably varied mean height gain of −1.8 to 15.0 cm. The variability must be explained, in part, by the small numbers in most of the study groups, but an analysis of 26 boys from three European studies showed a height gain of 6.2 cm (s.d. 8.7 cm). As was the case with treated girls, the height increment was greater when treatment was started early. GnRHa treatment in the case of adopted children with early puberty leads to a moderate height gain of 5.2 cm after 3 years of treatment.

Long-term outcome data after GnRHa treatment

More than 20 years of experience with GnRHa treatment in CPP has provided important data on outcome regarding reproduction, body mass index and bone mineral density. There is reassuring evidence that gonadal function is reactivated soon after cessation of treatment. Again, the information is confined mainly to females. Mean time to menarche post-treatment is 16 months with normal pattern of menses; reproductive potential appears normal in young adulthood with healthy offspring of those who became pregnant. There appears to be no increased risk of ovulatory dysfunction associated with factors such as hirsutism and polycystic ovary syndrome, and GnRHa treatment per se does not lead to obesity. However, fat mass is increased at the start of and during early treatment, but normalizes thereafter. Similarly, increased bone mineral density at the outset had normalized for both bone age and chronological age within 2 years of treatment cessation.

While there is evidence that early puberty can be associated with aberrant sexual activities and antisocial behaviour in late adolescence, there are no data on the effects of any treatment intervention on longer term outcome with respect to any psychopathologies. Embarking on treatment for the individual child with CPP is not underpinned by any comprehensive evaluation of the long-term outcome data at a population level.

Conclusions

It is estimated that precocious puberty affects between 1 in 5000 and 1 in 10 000 children and a high female to male ratio. There is consensus, at least in Europe, on the chronological age points below which onset of puberty is considered to be precocious in either sex. Puberty is a neurobiological phenomenon characterized by
re-awakening of the GnRH pulse generator; why this should occur on average at around 11 years of age in the human remains a biological mystery (38). The causes of precocious puberty are broadly subdivided according to a functional classification based on gonadotrophin dependence (central) and gonadotrophin non-dependence (peripheral). Central causes are amenable to management with GnRH analogues that operate on physiological principles by desensitizing the signalling pathway to gonadotrophin production. The aims of the treatment are to halt and perhaps reverse the secondary sex characteristics of puberty, prevent early onset of menses in girls and attenuate the loss of height potential consequent upon advanced skeletal maturation. These are the physical goals of the treatment intervention, but the psychosocial aspects are equally important to enable the child and family to cope better with the ‘mismatch’ between physical and emotional development. Gonadal steroid production is efficiently suppressed with GnRHa treatment, and menarche can be delayed until an age and developmental stage of choice agreed by the family and physician. There are no adverse effects in the longer term with respect to reproductive potential. Enhancing final height is not such a success story. This had encouraged a polypharmacy approach with the addition of GH to enhance growth velocity during the slow phase of growth while on GnRHa treatment and aromatase inhibitors (such as letrozole and anastrozole) to delay oestrogen-induced closure of the growth plate. This ‘belt and braces’ approach may be beneficial in individual cases, but there are no systematic controlled trials of its effectiveness on final height. Children with precocious puberty have to cope with the body image at variance with their chronological developmental stage within the context of their family, friends and in education. It is essential that included in the management of precocious puberty is supportive counseling comprising expertise in psychosocial aspects of developmental behaviour (39).

Disclosure

This paper forms part of a European Journal of Endocrinology supplement, supported by Ferring Pharmaceuticals. The authors disclose: no potential conflicting relationship with Ferring. This article was subject to rigorous peer review before acceptance and publication. The Symposium included a presentation by Dr JC Carel on the use of GnRH analogues in precocious puberty. Unfortunately, Dr Carel was unable to produce a manuscript emanating from his presentation for publication in the supplement. Supported by Ferring Pharmaceuticals. The authors confirm that the article was prepared without any potential conflicts of interest and that the article is a complete reflection of the research presented in the presentation.

References


3 Gluckman PD & Hanson MA. Evolution, development and timing of puberty. Trends in Endocrinology and Metabolism 2006 17 7–12.


5 Silveria LF, Santos MAG & Brito VN. Two KISS1 mutations associated with gonadotrophin-dependent precocious puberty. (abstract FC2-76) Hormone Research 2008 70 (Suppl 2) 20.


Received 23 October 2008
Accepted 29 October 2008